Valerion Therapeutics is utilizing a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a well-known and broadly studied transport pathway.
This platform is capable of enhanced intracellular delivery of a variety of active therapeutic payloads via a transport mechanism that is present in muscle and neurons and elevated in certain types of cancer. It also has the potential to treat cancers with DNA repair mutations.
Pipeline candidates include therapeutic agents aimed at addressing a host of orphan genetic disorders with limited or no current therapies.
Learn more: www.valerion.com